COMMUNIQUÉS West-GlobeNewswire

VERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models into R&D Strategy
07/10/2026
Consistent Use of New Approach Methodologies (NAMs) to Potentially Accelerate BiTAC® Oncology Pipeline and Significantly Reduce Animal Testing Needs ZURICH, SWITZERLAND, Oct. 07, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech [...]
Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia
07/10/2026
First patient enrolled in cohort combining bexobrutideg with venetoclax Initial cohort to focus on relapsed/refractory CLL, with potential expansion to first-line CLL Strategy includes evaluation of bexobrutideg given [...]
Oculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty Day
07/10/2026
Licaminlimab genotype-based precision medicine approach for TNFR1-mediated dry eye disease in PREDICT-1 registrational symptoms trial on track for topline readout around year-end ZUG, Switzerland, October 7, 2026 -- [...]
125,000 Orion Corporation A shares converted into B shares
07/10/2026
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 7 OCTOBER 2026 at 9.00 EEST 125,000 Orion Corporation A shares converted into B shares In accordance with [...]
Oculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty Day
07/10/2026
Licaminlimab genotype-based precision medicine approach for TNFR1-mediated dry eye disease in PREDICT-1 registrational symptoms trial on track for topline readout around year-end ZUG, Switzerland, October 7, 2026 -- [...]
PulseSight presents PST-611 Phase I new early clinical efficacy data at EURETINA, offering a potential breakthrough approach to treat Dry AMD/Geographic Atrophy
07/10/2026
PARIS, Oct. 07, 2026 (GLOBE NEWSWIRE) -- PulseSight Therapeutics SAS, an ophthalmology clinical-stage biotech company developing disruptive non-viral vectorized gene therapies with minimally invasive delivery technology [...]
Virbac : Déclaration d'actions et de droits de vote 09/2026
07/10/2026
DÉCLARATION D’ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d’actions composant le capital (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) [...]
Virbac : Declaration of the number of shares et voting rights 09/2026
07/10/2026
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial [...]
BIO-Europe C-Suite Survey: Biopharma dealmaking set to accelerate, but investor caution still caps ambition
07/10/2026
75% of biopharma leaders expect partnering and M&A appetite to increase over the next 12 months, none expect a decline 69% expect access to capital to improve, yet 79% identify investor risk aversion as the biggest [...]
Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes
07/10/2026
SAN CARLOS, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the pricing of concurrent underwritten public offerings of 7,412,500 [...]
OGRD Alliance Advances PLPC Multi-Asset Platform Following APHELAR Milestone, Expanding Licensing and Strategic Capital Frameworks
07/10/2026
DUBAI, United Arab Emirates, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Microdomain Science connects differentiated assets across personalized immuno-oncology, acellular biotechnology, MedTech and precision nutrition as OGRD [...]
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
06/10/2026
NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (the “Company”) (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer [...]
Acquisition of Own Shares
06/10/2026
Mechelen, Belgium; October 06, 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") [...]
BridgeBio to Present New Acoramidis Data, Including Independent Comparative Real-World EHR Data at the HFSA Annual Scientific Meeting 2026
06/10/2026
PALO ALTO, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for [...]
BridgeBio to Present Additional Evidence from the Phase 3 CALIBRATE Trial of Encaleret in ADH1 at the ASBMR 2026 Annual Meeting
06/10/2026
PALO ALTO, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for [...]
Achieve Life Sciences Announces Granting of New Hire Inducement Awards
06/10/2026
SEATTLE and VANCOUVER, British Columbia, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global [...]
Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026
06/10/2026
Oral presentation will highlight previously reported Phase 2 HORIZON data for MZE829 in patients with APOL1-mediated kidney disease Two poster presentations will highlight preclinical research supporting the therapeutic [...]
Equillium Announces Poster Presentation at the 50th Anniversary La Jolla Immunology Conference
06/10/2026
New preclinical data further characterizes EQ504’s coordinated effects across epithelial and immune compartments in intestinal inflammation LA JOLLA, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Equillium , Inc. (Nasdaq: [...]
Harvard Bioscience Announces Creation of Scientific Advisory Board
06/10/2026
HOLLISTON, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced the creation of its Scientific Advisory Board (SAB) to guide the Company’s ongoing research, development, and [...]

Pages